FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

AICAR

Acadesine / AICA Ribonucleotide / ZMP

Longevity & Anti-Aging

AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide, also known as Acadesine) is a synthetic analog of adenosine monophosphate that directly activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. Originally developed as a cardioprotective agent for use during cardiac surgery, it gained notoriety as an "exercise mimetic" capable of triggering metabolic adaptations typically associated with endurance training. AICAR is banned by the World Anti-Doping Agency (WADA) and is classified as a metabolic modulator on the prohibited substances list.

作用机制

AMP-kinase activator that mimics the metabolic effects of exercise. Increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis through direct AMPK phosphorylation. Shifts cellular metabolism toward an endurance-trained state.

研究协议

仅供研究使用,非医疗建议。

Research protocols use 150-500mg daily via subcutaneous injection. Animal studies used 500mg/kg. Often cycled 4-8 weeks. Sometimes combined with GW501516 in research settings.

研究笔记

Clinical Research Status

AICAR underwent Phase III clinical trials for reduction of ischemic injury during coronary artery bypass graft surgery, though it ultimately did not receive FDA approval for this indication. Research interest shifted dramatically after 2008 Salk Institute studies demonstrated that AICAR administration alone could improve running endurance in sedentary mice by 44%. It remains an investigational compound with no approved medical indications, though academic research into AMPK activation continues across metabolic disease, cancer, and aging fields.

Key Published Findings

The landmark Narkar et al. (2008) paper in Cell demonstrated that AICAR treatment for 4 weeks reprogrammed muscle metabolism toward oxidative fiber types and enhanced running endurance without exercise training. AMPK activation by AICAR increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis through PGC-1alpha signaling pathways. In cardiac ischemia studies, AICAR reduced post-surgical complications including atrial fibrillation and the need for inotropic support.

Safety Profile

Clinical trial data from cardiac surgery studies showed AICAR to be relatively well-tolerated at therapeutic doses, with hypoglycemia and lactic acidosis being the primary dose-limiting concerns. Renal toxicity has been observed at higher doses due to uric acid accumulation from purine metabolism. Long-term safety data in healthy populations is essentially nonexistent, as most human data comes from short-term perioperative use in cardiac patients.

Comparison to Related Compounds

Unlike GW501516 (Cardarine), which activates PPAR-delta downstream of AMPK, AICAR directly activates AMPK itself, affecting a broader range of metabolic pathways including autophagy and mTOR suppression. SLU-PP-332 represents a newer generation of exercise mimetics targeting estrogen-related receptors rather than AMPK. Metformin also activates AMPK but through indirect mitochondrial complex I inhibition rather than direct allosteric activation, resulting in a different pharmacological profile.

Community Observations

Users report enhanced endurance and fat oxidation, though the effects are considered modest compared to expectations set by animal studies. The high cost per effective dose and requirement for injection limit its practical use in performance enhancement contexts. Some users combine AICAR with GW501516 based on the original Salk Institute research showing synergistic effects, though this combination carries compounded safety unknowns.

半衰期

~2-3 hours

复溶

Bacteriostatic water (BAC) or sterile saline

存储

冻干

Refrigerate 2-8C up to 12 months.

复溶后

Refrigerate 2-8C. Use within 14 days.

美国法律状态

Research chemical (not FDA-approved)

又称作

AcadesineAICA RibonucleotideZMP

常见问题

什么是 AICAR?

AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide, also known as Acadesine) is a synthetic analog of adenosine monophosphate that directly activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. Originally developed as a cardioprotective agent for use during cardiac surgery, it gained notoriety as an "exercise mimetic" capable of triggering metabolic adaptations typically associated with endurance training. AICAR is banned by the World Anti-Doping Agency (WADA) and is classified as a metabolic modulator on the prohibited substances list.

AICAR 如何起作用?

AMP-kinase activator that mimics the metabolic effects of exercise. Increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis through direct AMPK phosphorylation. Shifts cellular metabolism toward an endurance-trained state.

AICAR 在美国的监管状态是什么?

Research chemical (not FDA-approved)

AICAR 的半衰期是多少?

~2-3 hours

AICAR 还有哪些名称?

Acadesine, AICA Ribonucleotide, ZMP

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明